rimary percutaneous coronary intervention (PCI) in patients with acute myocardial infraction (AMI) has been shown to be preferable to thrombolytic therapy in terms of patient survival, higher rates of patency in the infarcted arteries, and lower rates of reinfarction and stroke. 1,2 These benefits of PCI can be further enhanced by administration of platelet glycoprotein IIb/IIIa inhibitors abciximab 3-7 or eptifibatide. 8, 9 Tirofiban 10 stands out as a potentially useful adjunct to PCI because it is a small non-peptide molecule, somewhat similar to eptifibatide, and does not elicit an adverse immune reaction. Compared with abciximab, its advantages as an adjunct therapy for PCI are lower cost and no overt bleeding complications. 11 Results from studies of the efficacy of adjunctive tirofiban in patients undergoing PCI have been inconsistent. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Some have shown beneficial angiographic and clinical outcomes, 20,22 whereas others show either no benefit 16 or modest initial clinical improvements, unsustained at 30-day follow-up. 13, 17 Interpretation of these results is difficult because different dosing regimens were used; for example, tirofiban was administered at a conventional dose (10 g/kg bolus followed by 0.15 g·kg -1 ·min -1 for 18-36 h) in some studies [12] [13] [14] [15] 17, [21] [22] [23] and in others 16, [18] [19] [20] [21] at a high dose (20-25 g/kg bolus followed 0.15 g·kg -1 ·min -1 for 18-24 h). The conventional dose of tirofiban may not achieve adequate platelet aggregation inhibition compared with abciximab. 14, 15, 24 Timing of the administration of tirofiban before PCI also varied, 12-23 and patients with different clinical scenarios of acute coronary syndrome were studied. These factors are all likely to influence the results and so it remains unclear what the optimal regimen of adjunctive tirofiban therapy would be for PCI in various patient populations. This study was undertaken to examine the angiographic and clinical outcomes in patients with ST-segment elevation AMI (STEMI) undergoing PCI with a double bolus regimen of tirofiban therapy.
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Methods

Patients
Between August 2000 and December 2001 we prospectively enrolled 217 patients with AMI with ST-segment elevation 0.1 mV in 2 or more contiguous leads on electrocardiogram (ECG) who were candidates for PCI within 12 h of onset of symptoms or within 18 h of onset of symptoms if cardiogenic shock occurred. Patients were excluded from the study if any of the following were present: bleeding diathesis, neoplasm, recent stroke, uncontrolled hyperten-sion, recent surgery, oral anticoagulant therapy, a limited life expectancy, childbearing potential, known contraindications to therapy with aspirin, ticlopidine, clopidogrel and heparin, or if they had been administered thrombolytic agents for the current episode. The decision to receive tirofiban or not was made at the discretion of the attending physicians. All patients gave informed written consent and all procedures followed institutional guidelines.
Study Protocol
All patients took 1 dose of aspirin (324 mg po) immediately, as well as appropriate antianginal medications, in the emergency room (ER). The patients selected by physicians to receive tirofiban (tirofiban group) were administered 1 intravenous bolus tirofiban of 10 g/kg in the ER and after arrival at the cardiac catheterization laboratory, another IV bolus of tirofiban of 10 g/kg was administered over 3 min followed by infusion at a rate of 0.15 g·kg -1 ·min -1 for a total dose of 12.5 mg. These patients were also given a bolus of heparin of 60 U/kg up to a maximum dose of 7,500 U and, if necessary, a supplementary dose to achieve an activated clotting time (ACT) ≥200 s. The patients not receiving tirofiban served as the control group and only received 10,000 U heparin in the cardiac catheterization laboratory with a target ACT >300 s. After the procedure, heparin was discontinued in both groups of patients.
Target vessel revascularization (TVR) was performed at the discretion of individual operators. If stents were deployed, clopidogrel (300 mg orally followed by 75 mg daily for at least 4 weeks) or ticlopidine (500 mg orally followed by 250 mg twice a day for at least 4 weeks) was administered. All patients continued to receive aspirin 100-324 mg per day. Other medications, including -blockers, nitrates, and morphine were administered at the discretion of individual attending physicians.
Angiographic Analysis
Coronary angiography was performed according to standard acquisition guidelines and the images were analyzed by experienced interventionists who were unaware of the patients' clinical outcomes. Quantitative coronary artery analyses of the percentage of minimal lumen diameter stenosis, lesion length and reference vessel diameter were performed using a digital edge-detection algorithm. Four acute angiographic parameters (Thrombolysis In Myocardial Infarction (TIMI), TIMI myocardial perfusion (TMP), 25 corrected TIMI frame counts (CTMFC) 26 and thrombus score 27 ) were also evaluated. These are important independent predictors of late lumen loss and adverse cardiac events 28 and reduced survival in patients with TIMI grade III flow. 29 
Data Collection
The following timepoints were recorded 3 times For each patient: time from initial onset of chest pain to arrival at the ER (onset to door), time from initial ER arrival to tirofiban administration (door to drug), and time from initial ER arrival to the first angioplasty balloon inflation (door to balloon). In the ER, patient characteristics were also recorded (ie, age, gender, coronary risk factors, Killip classification, blood pressure and heart rate).
Creatinine kinase isoemzyme levels were measured at baseline before PCI and every 8 h for 24 h after the procedure or when there was any clinical evidence of myocardial ischemia.
After the procedure, patients were followed up at least monthly.
The primary endpoint was a composite of cardiovascular death, reinfarction, or urgent TVR within 30 days and at 1 year after PCI. Reinfarction was defined according to clinical symptoms and new ECG changes with a new elevation of creatine kinase MB isoenzyme. 25 Urgent TVR was defined as repeat PCI or coronary artery bypass grafting performed within 24 h after a new ischemic episode. Bleeding complications were defined as major or minor according to the TIMI classification 30 and severe thrombocytopenia was defined as platelet count of less than 50,000 /mm 3 .
Statistical Analysis
Continuous data are presented as mean ± SD and were compared using Student's t-test or Wilcoxon rank sum test between 2 groups. Categorical variables were compared using chi-square or Fisher's exact test. Time to the first occurrence of the primary endpoint was displayed with a Kaplan-Meier survival curve. The log-rank test was used to compare survival in the tirofiban and control groups. The Cox proportional hazards model was used to calculate adjusted hazard ratios based on the time to the event.
Stepwise logistic regression analysis was used to determine independent predictors of clinical outcomes after intervention treatment. Because patients with Killip III and IV AMI had similar primary endpoints in this study, Killip III and IV were regarded as one independent predictor. Statistical analysis was performed using a statistical software program (SAS version 6.12; SAS Institute, Cary, NC, USA). Probability values of less than 0.05 were considered statistically significant. The relative risk and its 95% confidence interval are also presented.
Results
Clinical Characteristics of the Study Patients
A total of 217 patients were enrolled: 137 in the tirofiban group and 80 in the control group. The 2 groups were well matched with respect to baseline characteristics and key angiographic features (Table 1) . Angiographic studies demonstrated no significant differences in the infarct-related vessel, incidence of multivessel disease, or in pre-interventional TIMI flow grades between the 2 groups. In the tirofiban group, 7.3% of patients had a Killip III AMI and 13.9% of patients had a Killip IV AMI compared with 11.3% (p=0.224) and 21.3% (p=0.116) in the control group. The onset-to-door time and the door-to-balloon time did not differ significantly between the 2 groups. In the tirofiban group, the second bolus of tirofiban was given at an average of 52.4±29.8 min after the first.
Angiographic Data Before and After Angioplasty
Several angiographic measures in the 2 groups were statistically identical ( Table 2 ). The thrombus burden and TIMI flow grade before PCI were not significantly different between the 2 groups. Immediately after the procedure, the proportion of patients with slow re-flow and no re-flow (TIMI flow grade 0-2) phenomenon was similar in the tirofiban (16.2%) and control groups (15.0%; p=0.974). Likewise, the proportion of patients who were hyperemic after the procedure (CTMFC <14) was similar in the 2 groups. TMP grade 3 was achieved in 16.1% in the tirofiban group and 13.8% in the control group (p=0.628). A possible or definite (small, medium, or large) intracoronary thrombus was seen in 26.3% of patients in the tirofiban group and in 28.7% of patients in the control group (p=0.423).
Incidence of Primary Endpoint in 1 Year and Bleeding Complications During the 30-Day Period
The incidence of the primary endpoints in the tirofiban group was 5.1% in the first 30 days after enrollment, which was statistically similar to that in the control group (10.0%, p=0.171) (data not shown in Table 3 ). This statistically insignificant trend persisted into the 1-year study period with 11.7% incidence of the primary endpoints in the tirofiban group compared with 18.8% in the control group (p=0.151) ( Table 3 ; Fig 1) . Specifically, the 30-day cardiovascular mortality rates in patients with Killip class ≥III were similar in the tirofiban and control groups (Killip III: 20% vs 11.1%, p=0.596; Killip IV: 21.1% vs 23.5%, p=0.858). Likewise, there were no differences between the groups in the mortality rates at 1 year (Killip III: 20.0% vs 22.2%, p=0.906; Killip IV: 26.4% vs 23.5%, p=0.563). After excluding patients in Killip III and IV, the primary endpoints remained statistically similar at 30 days and 1 year in the 2 groups (p=0.216 at 30-days and p=0.216 at 1-year).
There was no significant difference in the rates of major or minor bleeding complications between the groups during the 30-day period (Table 3 ). The overall rates were statistically identical.
Determinants of Clinical Outcome in the Study Patients
Univariate logistic analyses of the 7 factors associated with outcome are shown in Table 4 : smoking, Killip classification, TMP grade, post-intervention thrombus score, post-intervention TIMI flow, post-intervention CTMFC, and bleeding complications. Only 3 variables (ie, smoking, Killip classification, and TMP grade) were significantly independent predictors of major adverse cardiac events as determined from multivariate stepwise logistic regression analysis (Table 5 ).
Discussion
Our hypothesis that in patients STEMI undergoing PCI, a double bolus regimen of tirofiban would be effective in improving angiographic and clinical outcomes is not conclusively supported by our study.
Using a standard regimen (a bolus of 10 g/kg immediately before the procedure followed by a maintenance infusion at a rate of 0.15 g·kg -1 ·min -1 for 24 h), previous studies found that adjunctive tirofiban therapy in PCI conferred protection against early adverse cardiac events related to thrombotic closure, 13 but failed to have significant effect on cardiac events at 30 days. 13, 17 Probably as a result of suboptimal early inhibition of platelets by tirofiban as compared with abciximab, 15 this dosing regimen was reported to be inferior to abciximab for protecting against death, nonfatal myocardial infarction, or urgent TVR. 14 In contrast, a higher dose (tirofiban 25 g/kg bolus followed by infusion at a rate 0.15 g·kg -1 ·min -1 ) that has better platelet aggregation inhibition than abciximab 18 can achieve similar efficacy to abciximab on initial angiographic results and 30-day recovery of left ventricular function in patients with STEMI 18 or acute coronary syndrome 19 undergoing primary PCI. As compared with placebo, Valgimigli et al also showed this high dosing regimen was able to significantly improve clinical and angiographic outcomes in patients undergoing high-risk PCI. 20 In our study, we administered tirofiban for a total dose of 20 g/kg by 2 consecutive boluses of 10 g/kg before PCI, and so did not reach the high dosages reported earlier.
Timing of its administration is likely to play a role in the results. In many studies, tirofiban was injected immediately before PCI in the catheterization laboratory, with inconsistent results. 10, [12] [13] [14] [15] [18] [19] [20] [21] [22] Early administration of tirofiban improved angiographic outcome in subjects undergoing PCI for AMI in the TIGER-PA Pilot trial. 17 The potential importance of the timing of administration is also consistent with another study 21 in which, if tirofiban was administered after angiographic study but just before PCI, angiographic outcomes in patients receiving low and high doses were similar, even though there was a clear dose-related platelet aggregation inhibition. In this study, we explored the potential benefit of dissolution of platelet thrombi by tirofiban 31 with early administration of 1 dose to patients at presentation to the ER and a booster dose in the catheterization laboratory before the procedure, but this regimen did not significantly improved acute angiographic and clinical outcomes (Table 3 ). In our study, smoking, Killip classification, and TMP grading remained the only statistically significant independent predictors of clinical outcomes.
Several reasons may explain the statically insignificant results in our study. One could be the result of a small number of study patients (ie, a type 2 error), and the type of study patients no doubt has an effect on the outcome. All of our study patients had STEMI, but such patients were excluded in Valgimigli et al's study. 20 We also enrolled a sizable portion of patients with ≥Killip III AMI (Table 1) , which has a relatively high mortality. All of our study patients were Oriental and it is uncertain if there is a racial difference in the dose of tirofiban required for effective therapy. Thus, in addition to a different dosing regimen that might explain the differences between our results and others, [18] [19] [20] 22 the severity of disease and racial difference need to be taken into consideration. However, the trend toward favoring the double bolus regimen to reduce the composite primary endpoints at 30-day (absolute reduction 4.9% and relative reduction 49%, p=0.171) and at 1-year follow-up (absolute reduction 7.1% and relative reduction 37.7%, p=0.151) (Table 3) suggests that with further refinement of the protocol, this regimen has a high potential adjunctive benefit.
Study Limitations
The limitations include an unevenly distributed, relatively small sample size, and lack of randomization of the study patients. The relatively small sample size may have limited the statistical power to detect the benefits of tirofiban. Studies of glycoprotein IIb/IIIa inhibition with new therapies (antithrombin therapies, 32 factor Xa inhibitors, 5-HT2 receptor blocker 33 ) and devices (distal protection) 16, 19 should refine the effective algorithms and provide guidance for the optimal use of GP IIb/IIIa inhibitors in evidence-based medical practice.
Conclusions
Our study demonstrates that a regimen of double-bolus adjunctive tirofiban in PCI in patients with STEMI is safe and feasible. Although benefits in acute angiographic results and clinical outcomes were not clearly demonstrated, our results do suggest that research into an effective and uniform dosing regimen of adjunctive tirofiban therapy for PCI in a large clinical trial is highly warranted.
